Evidence map›Paper›PMID 41179094›Full record

ArticleCureus2025

The Invisible Controller: A Decade-Long Missed Diagnosis of HIV in a Socially Vulnerable Elite Controller.

Hafiz Fadl, Nicolas Bakinde, Minnie Mitchell, Keyera Ashe

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hafiz FadlInternal Medicine, Morehouse School of Medicine, Atlanta, USA.
Nicolas BakindeInternal Medicine, Morehouse School of Medicine, Atlanta, USA.
Minnie MitchellInternal Medicine, Morehouse School of Medicine, Atlanta, USA.
Keyera AsheInternal Medicine, Morehouse School of Medicine, Atlanta, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elite controllers (ECs) are rare individuals living with HIV who maintain viral suppression without antiretroviral therapy (ART). Their unique immune responses have contributed significantly to HIV cure research. However, in populations burdened by psychiatric illness and housing insecurity, such cases may go undetected, raising important ethical, clinical, and public health concerns. We present the case of a 62-year-old African American woman with schizophrenia, bipolar disorder, traumatic brain injury, and unstable housing who was hospitalized after a ground-level fall. During routine testing, she was found to be HIV-positive with a CD4 count of 1267 cells/mm³ and an undetectable viral load, despite denying any knowledge of an HIV diagnosis. A review of past records revealed an HIV-positive result from 2015, with no evidence of follow-up, disclosure, or treatment, indicating a decade-long missed opportunity. Despite never receiving ART, she met criteria for elite controller status, highlighting the intersection of rare immunologic phenomena and profound inequities in HIV detection and care. The patient's intersecting vulnerabilities - including race, gender, homelessness, psychiatric illness, and inconsistent healthcare engagement - conspired to keep her diagnosis undisclosed for years, vulnerable to disease progression and unknowingly transmitting HIV. In an era pursuing an HIV cure, the identification of such individuals is not merely a research priority but an ethical imperative for advancing public health equity.

Indexed as

antiretroviral therapyelite controllerfunctional hiv curehiv aidshiv transmission riskpublic health equitysevere mental illnesssocial determinants of healthundiagnosed hivviral suppression

Identifiers

PMID41179094
PMCPMC12576358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.